Therapeutics & Pipeline

Amsoki-Cel Shows 66.7% Response in Advanced ICI-Resistant Melanoma

Marco Donia: TIL Therapy Without Systemic IL-2 in Melanoma
Parentingupstream / pixabay

By Olivia Hart

A pooled analysis of two early-phase trials found an objective response rate of 66.7% (10 of 15; 95% CI, 38%-88%) and two complete responses among 15 patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma who received amsoki-cel (OBX-115) at the recommended phase 2 dose (RP2D). The phase 1 and phase 1/2 studies treated 37 patients overall.

At the RP2D, median progression-free survival (PFS) was 8.1 months, with a 95% CI of 3.9 months to not estimable. Median follow-up was 8.3 months, ranging from 4.1 to 21.4 months.

The 66.7% estimate translates to roughly two responses in every three patients at the RP2D, but the 38%-88% confidence interval and 15-patient denominator limit its precision. With median follow-up at 8.3 months, the 8.1-month median PFS does not establish how durable the responses will be.

Across all 37 patients, investigators reported no dose-limiting toxicities, no intensive-care-unit admissions, no immune effector cell-associated neurotoxicity syndrome (ICANS) and no treatment-related deaths. They recorded one grade 3 cytokine release syndrome (CRS). Grade 3 or higher toxicity was predominantly hematologic, with neutropenia in 64.9%; serious nonhematologic events occurred in 13.5%.

The safety analysis therefore covered all 37 treated patients, while the reported response estimate and protocol details at the RP2D came from 15. Grade 3 or higher neutropenia affected roughly two-thirds of the safety cohort, making hematologic monitoring a central part of the early safety profile.

Amsoki-cel is an investigational tumor infiltrating lymphocyte (TIL) product engineered to express membrane-bound IL-15 (mbIL15), regulated by oral acetazolamide. Historically, high-dose IL-2 enabled TIL therapy, but its toxicity limited both the patients who could tolerate it and the centers able to deliver it.

Marco Donia, Professor of Clinical Oncology at the University of Copenhagen, wrote on LinkedIn: “No systemic IL-2 after infusion. IL-2 is still used in the pre-REP phase of manufacturing, but mbIL15 removes it from the expansion phase.”

That distinction matters because the regimen is free of systemic IL-2 after infusion, not throughout the entire manufacturing process. The source report says IL-2 remains part of the pre-REP phase, while mbIL15 replaces it during expansion.

All 15 patients at the RP2D received low-dose lymphodepletion, and every acetazolamide re-dose occurred in the outpatient setting. Donia linked those protocol features to the potential for broader accessibility.

Donia wrote: “Removing systemic IL-2, lowering the intensity of lymphodepletion and moving re-dosing to the outpatient clinic would make the regimen deliverable in many more departments.” He paired that view with a caution: tumor procurement, individualized manufacturing and lymphodepletion itself remain real barriers.

What does this change for patients?

Within the trial, the practical change is an investigational TIL regimen without systemic IL-2 after infusion and, at the RP2D, low-dose lymphodepletion plus outpatient acetazolamide re-dosing. If the approach holds, Donia said, more departments could deliver it.

The access benefit is not yet established. Amsoki-cel remains investigational, and tumor procurement, individualized manufacturing and lymphodepletion still constrain who can receive treatment and where it can occur. The early safety results also do not yet show how the regimen performs outside the 37-patient cohort.

Longer follow-up of the same 15 patients must show whether the responses hold. Agni-01 cohort 3 (NCT06060613) then tests the response rate in a larger sample. Donia described the possibility that a lighter regimen could widen access to treatment as plausible, but not yet tested.

Study record

The report is titled “Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials.”

Its listed authors are Rodabe N. Amaria, Jason A. Chesney, Allison S. Betof, Gino K. In, Alexander N. Shoushtari, Tirrell T. Johnson, Omid Hamid, Yazan Samhouri, Michael A. Davies, Hussein A. Tawbi, Isabella C. Glitza Oliva, Bulent Arman Aksoy, Amanda M. Kelly, Raina Duan, Prakash Prabhakar, Giridharan Ramsingh, Madan Jagasia and Parameswaran Hari.

Donia said the work had been reviewed for Nature Medicine and that he wrote the post with Yago Garitaonaindia. He congratulated Amaria, Chesney, Betof and all investigators, as well as Hari and the Obsidian Therapeutics team. He also thanked the patients who agreed to take part in the first-in-human studies.

The next test is whether these early responses persist with longer follow-up and whether Agni-01 cohort 3 shows a similar response rate in a larger sample; wider delivery will also depend on overcoming procurement, individualized manufacturing and lymphodepletion barriers.

Source: oncodaily.com

Share this article:

Olivia Hart

Show full bio

News editor covering technology and product news in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.

More from Olivia Hart →

Related articles

« Previous articleNext article »